This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Staphylococcus aureus (Staph) is a germ that can cause skin infections and other serious and deadly infections. Community-Associated methicillin-resistant Staphylococcus aureus (CA-MRSA) are types of Staph infections that are resistant to many antibiotics. CA-MRSA infections are suddenly very common, whereas 10 years ago they were unheard of. CA-MRSA are resistant to many antibiotics so doctors are not sure which antibiotics work best against skin infections, which are now caused mostly by CA-MRSA. To understand how to best treat skin infections, specifically ones called ?uncomplicated skin and soft tissue infections? (uSSTIs), we need to do a clinical trial to compare antibiotics that experts think are best. However, there is no proof about how good (efficacious) or safe these antibiotics are. We will perform a clinical trial of treatment of uSSTIs --specifically treatment of abscesses (boils) and/or cellulitis (bland skin infection)--in both children and adults in areas where CA-MRSA is common. The primary objective of this study is to compare the cure rates of two antibiotics, clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) for the treatment of uSSTIs. Treatment will be done in conjunction with the standard of care for treatment of abscesses, which is incision and drainage (i.e., lancing a boil). There is preliminary information that incision and drainage alone without antibiotics may be sufficient for patients with small abscesses. Therefore, subjects with small abscesses will be randomized to be treated with either clindamycin, TMP-SMX, or placebo.
Showing the most recent 10 out of 1232 publications
